Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Aims We conducted a systematic review and meta-analysis on three outcomes. We
assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Background Patients with obesity were underrepresented in studies evaluating the safety
and effectiveness of direct oral anticoagulants (DOAC) in patients with non-valvular atrial …

Background Morbidly obese (body mass index [BMI]> 40 kg/m 2) patients undergoing total
joint arthroplasty (TJA) are at high risk for postoperative venous thromboembolism (VTE); …

Pulmonary embolism (PE) can present with a range of severity. Prognostic risk stratification
is important for efficacious and safe management. This second of two review articles …

Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …

Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …

Background: Extremes of body weight may alter exposure to non-vitamin K antagonist oral
anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis …

Abstract Background and Objective Rivaroxaban and apixaban are direct oral
anticoagulants increasing in popularity as convenient alternatives to warfarin. However …